Zanolimumab
Jump to navigation
Jump to search
Template:Short description Template:Drugbox Zanolimumab is an investigational human monoclonal antibody and an immunosuppressive drug.[1] It was developed with the goal of treatment of rheumatoid arthritis, psoriasis, melanoma,[2] cutaneous and peripheral T-cell lymphoma.[3][4] Development of the drug was ultimately discontinued with termination of all trials.[5]
References
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab Template:Webarchive, American Medical Association.
- ↑ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
- ↑ Script error: No such module "citation/CS1".
Script error: No such module "Navbox". Script error: No such module "Navbox".